


# UBS Swiss High Dividend Equity Fund CHF

## Performance **Review**

UBS (CH) Equity Fund - Swiss High Dividend (CHF) Q



### Performance (basis CHF, net of fees)<sup>1</sup>



**Past performance is not a reliable indicator of future results.**

### Performance in % (net of fees)<sup>1</sup>

in %	2021	2022	2023	2024	2025 YTD <sup>2</sup>	Jan. 2025	5 years Ø p.a. 5 years
Fund (CHF)	17.42	-12.16	9.22	11.38	6.34	6.34	36.38
Benchmark <sup>3</sup>	23.38	-16.48	6.09	6.18	8.20	8.20	30.07

The performance shown does not take account of any commissions, entry or exit charges.

<sup>1</sup> These figures refer to the past. **If the currency of a financial product, financial service or its costs is different from your reference currency, the return and/or costs can increase or decrease as a result of currency fluctuations.** Source for all data and chart (if not indicated otherwise): UBS Asset Management.

<sup>2</sup> YTD: year-to-date (since beginning of the year)

<sup>3</sup> Reference Index in currency of share class (without costs)

**Swiss equities made a positive start to 2025. Despite increased volatility driven by uncertainty surrounding potential US tariffs, the market was supported by robust corporate results. January saw technology and consumer discretionary outperform the market, while basic materials and consumer staples lagged behind.**

### Monthly performance

In January the fund performed positively with 6.3%. During January, relative performance was driven by negative allocation effects from consumer discretionary and basic materials, as well as stock selection in industrials and financials.

### YTD performance

YTD as of the end of January, the fund has delivered a positive performance of 6.3%. Please refer to the section above.

### Performance contributors

Novartis, Nestlé and Lonza contributed positively to absolute performance in January. Novartis traded higher after the company comfortably beat earnings expectations. Lonza also traded higher after releasing robust results for Q4/full-year 2024 and a positive outlook for 2025 and beyond.

### Performance detractors

In January, Barry Callebaut, SFS and SGS were the biggest detractors from absolute performance. Barry Callebaut continued to suffer due to higher cocoa prices. SFS presented preliminary sales figures and a margin that came in at the lower end of expectations. Meanwhile, SGS announced that the company could not reach agreement on a merger with Bureau Veritas.

### For more information

UBS Fund Infoline: 0800 899 899

Internet: [www.ubs.com/funds](http://www.ubs.com/funds)

Contact your client advisor

### Portfolio management representatives

Bernhard Lüthi

Christian Suter

Florian Töpfl

# UBS Swiss High Dividend Equity Fund CHF

## Sector exposure (%)

	Fund
Financials	32.6
Health Care	24.2
Industrials	14.9
Materials	11.6
Consumer Staples	10.4
Consumer Discretionary	2.8
Communication Services	2.5
Information Technology	0.4
Real estate	0.2
Others	0.4

## 10 largest equity positions (%)

	Fund
Roche Holding AG	9.70
Nestle SA	9.45
Novartis AG	9.27
UBS Group AG	9.05
Zurich Insurance Group AG	8.37
ABB Ltd	6.69
Swiss Re AG	6.24
Givaudan SA	4.65
Holcim AG	4.20
Lonza Group AG	3.73

## Current investment strategy

Long-term fundamentals are intact for the Swiss market. We are watching market and company developments closely with a view to finding attractive investment opportunities in the current environment. Besides identifying companies that prove resilient, we analyse dividend expectations and their impact on our investment cases.

## Risks

This fund invests in equities and may therefore be subject to high fluctuations in value. As these UBS funds pursue an active management style, each fund's performance can deviate from that of its reference index. All investments are subject to market fluctuations. Every fund has specific risks, which can significantly increase under unusual market conditions. The fund can use derivatives, which may result in additional risks (particularly counterparty risk).

Please note that additional fees (e.g. entry or exit fees) may be charged. Please refer to your financial adviser for more details. Investors should read the Key Information Document, Prospectus and any applicable local offering document prior to investing and to get complete information of the risks. Investors are acquiring units or shares in a fund, and not in a given underlying asset such as building or shares of a company. For a definition of financial terms refer to the glossary available at [www.ubs.com/am-glossary](http://www.ubs.com/am-glossary).

**For marketing and information purposes by UBS.** UBS funds under Swiss law. Arrangements for marketing fund units mentioned in this document may be terminated at the initiative of the management company of the fund(s). Prospectuses, key information document, the articles of association or the management regulations as well as annual and semi-annual reports of UBS funds are available in a language required by the local applicable law free of charge from UBS Asset Management Switzerland AG, c/o UBS AG, Bahnhofstrasse 45, 8001 Zürich or from UBS Fund Management (Switzerland) AG, P.O. Box, CH-4002 Basel. The benchmark is the intellectual property of the respective index provider. The fund or the share class is neither sponsored nor endorsed by the index provider. The fund prospectus or supplemental prospectus contains the full disclaimer. Before investing in a product please read the latest prospectus and key information document or similar legal documentation carefully and thoroughly. Any decision to invest should take into account all the characteristics or objectives of the product as described in its prospectus, or similar legal documentation. Investors are acquiring units or shares in a fund, and not in a given underlying asset such as building or shares of a company. The information and opinions contained in this document have been compiled or arrived at based upon information obtained from sources believed to be reliable and in good faith, but is not guaranteed as being accurate, nor is it a complete statement or summary of the securities, markets or developments referred to in the document. Members of the UBS Group may have a position in and may make a purchase and / or sale of any of the securities or other financial instruments mentioned in this document. Units of UBS funds mentioned herein may not be eligible for sale in all jurisdictions or to certain categories of investors and may not be offered, sold or delivered in the United States. The information mentioned herein is not intended to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. Past performance is not a reliable indicator of future results. The calculated performance takes all costs on the product level into consideration (ongoing costs). The entry and exit costs, which would have a negative impact on the performance, are not taken into consideration. If whole or part of the total costs to be paid is different from your reference currency, the costs may increase or decrease as a result of currency and exchange rate fluctuations. Commissions and costs have a negative impact on the investment and on the expected returns. If the currency of a financial product or financial service is different from your reference currency, the return can increase or decrease as a result of currency and exchange rate fluctuations. This information pays no regard to the specific or future investment objectives, financial or tax situation or particular needs of any specific recipient. Future performance is subject to taxation which depends on the personal situation of each investor and which may change in the future. The details and opinions contained in this document are provided by UBS without any guarantee or warranty and are for the recipient's personal use and information purposes only. This document may not be reproduced, redistributed or republished for any purpose without the written permission of UBS Asset Management Switzerland AG or a local affiliated company. Source for all data and charts (if not indicated otherwise): UBS Asset Management. This document contains statements that constitute "forward-looking statements", including, but not limited to, statements relating to our future business development. While these forward-looking statements represent our judgments and future expectations concerning the development of our business, a number of risks, uncertainties and other important factors could cause actual developments and results to differ materially from our expectations. A summary of investor rights in English can be found online at [www.ubs.com/funds-regulatoryinformation](http://www.ubs.com/funds-regulatoryinformation). More explanations of financial terms can be found at [www.ubs.com/am-glossary](http://www.ubs.com/am-glossary).

© UBS 2025. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.